Loading
Chairs the European MCL Network and led TRIANGLE, which showed ibrutinib can replace transplant in younger mantle cell lymphoma patients.
Martin Dreyling leads the European Mantle Cell Lymphoma Network, whose MCL Younger and Elderly trials established cytarabine-based induction with autologous transplant and rituximab maintenance, and was principal investigator of TRIANGLE, which showed adding ibrutinib to first-line therapy improves outcomes and that transplant adds nothing once ibrutinib is given, a shift toward chemotherapy-light care. He chairs ESMO lymphoma guideline work.
A second randomised confirmation that adding a Bruton tyrosine kinase inhibitor to first-line bendamustine-rituximab delays progression in older patients with mantle cell lymphoma, with a toxicity profile that did not improve as much as the drug's selectivity promised.
Twenty-eight extra months of progression-free survival, with no survival gain and a high rate of severe adverse events in both arms. It set up the two trials that followed: ECHO, which substituted a more selective inhibitor, and ENRICH, which removed the chemotherapy.
Chemotherapy-free cellular therapy for follicular lymphoma that has stopped responding, with a toxicity profile mild enough that the treatment is deliverable outside the largest centres.
Shares Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma, Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma, SHINE, Mantle cell lymphoma and the tags lymphoma, mantle-cell.
Shares Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma, Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma, SHINE, CD20.
Shares Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial, ELARA, CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma.
Shares Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma, Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma, SHINE, CD20.
Shares the tags lymphoma, cooperative-group.
Shares Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma, Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma, SHINE, Mantle cell lymphoma.
Shares Small-molecule kinase inhibitors and the tag cooperative-group.
Shares Small-molecule kinase inhibitors and the tag cooperative-group.